Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.31 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11189202 | 0.85 | CYP2A6 (0.38) | CYP2A6NOS3NOS1NOS2KDM4E | |
| SCHEMBL206008 | 0.81 | EGFR (0.33) | — | |
| SCHEMBL207265 | 0.71 | AHR (0.37) | CYP2A6ALDH1A1 | |
| SCHEMBL4152683 | 0.71 | RAB9A (0.42) | KDM4EALDH1A1GAA | |
| SCHEMBL11518261 | 0.68 | CYP2A6 (0.47) | CYP2A6NOS3NOS1NOS2KDM4E | |
| SCHEMBL940594 | 0.68 | ALDH1A1 (0.44) | CYP2A6KDM4EALDH1A1 | |
| SCHEMBL5140691 | 0.68 | MEN1 (0.41) | — | |
| SCHEMBL5345579 | 0.67 | FGFR1 (0.37) | ABCG2 | |
| SCHEMBL208752 | 0.67 | MAP3K14 (0.33) | — | |
| SCHEMBL407727 | 0.67 | PKM (0.45) | NOS3NOS2KDM4EKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | claimed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240201205-A1 | METHOD FOR DETECTING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024059845-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-21 | — | — | WO | disclosed |
| US-9408392-B2 | Compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-20140378461-A1 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-12-25 | — | — | US | disclosed |
| EP-2814321-A2 | NEMATICIDAL CIS (HETERO)ARYLCYCLOPROPYLCARBOXAMIDE DERIVATIVES | Syngenta Participations AG (CH) | 2014-12-24 | — | — | EP | disclosed |
| WO-2013120940-A2 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-08-22 | — | — | WO | disclosed |
| US-7309718-B2 | Dibenzocycloheptene compound | UBE INDUSTRIES, LTD. (JP) | 2007-12-18 | — | — | US | disclosed |
| US-4172081-A | Benzotriazole ultraviolet stabilizers | EASTMAN KODAK COMPANY (US) | 1979-10-23 | — | — | US | disclosed |
| US-4162254-A | Benzoxazole ultraviolet stabilizers | EASTMAN KODAK COMPANY (US) | 1979-07-24 | — | — | US | disclosed |
| US-4137235-A | ULTRAVIOLET STABILIZERS IN POLYMERIC COMPOSITIONS | EASTMAN KODAK COMPANY (US) | 1979-01-30 | — | — | US | disclosed |
| US-4116928-A | Heterocylic ester, ultraviolet stabilizers and their use in organic compositions | EASTMAN KODAK COMPANY (US) | 1978-09-26 | — | — | US | disclosed |
| US-4116929-A | POLYESTERS | EASTMAN KODAK COMPANY (US) | 1978-09-26 | — | — | US | disclosed |
| US-4096115-A | Ultraviolet light stabilized polymers | EASTMAN KODAK COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
| US-4065427-A | Polychromophoric heterocyclic ultraviolet stabilizers and their use in organic compositions | EASTMAN KODAK COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4017508-A | POLYMERS | EASTMAN KODAK COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
| US-4000148-A | POLYMERS | EASTMAN KODAK COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | CYP2A6 4848/4885NOS3 3788/4885NOS1 4315/4885 |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | CYSLTR2, CYSLTR1, LTC4S | CYP2A6 772/4885NOS3 178/4885NOS1 60/4885 |
| US-20140378461-A1 | NOVEL COMPOUNDS | CYP1B1, DDT, CYP51A1 | CYP2A6 306/4885NOS3 2827/4885NOS1 2025/4885 |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | PRNP, PSEN1, SNCA | CYP2A6 4714/4885NOS3 3968/4885NOS1 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.